RP1: Initial data in new indications expected in 2021 in anti-PD1 failed NSCLC, anti-PD1 failed CSCC and CSCC solid organ transplant recipient patients; further updates expected to be provided across all studies RP2: Initial data to be reported in 2021 in combination with Opdivo in Phase 1 all